Facebook
Twitter
LinkedIn
ForwardSponsored Session: Safely Managing Antibiotics Through Procalcitonin Measurement
Session Description:
Sponsored by Siemens Healthineers
This sponsored session will discuss how measuring procalcitonin (PCT) in patients with sepsis can help healthcare professionals to establish the concept of bacterial burden, safely manage antibiotics, and improve clinical and financial outcomes. Learners will review the diagnostic and treatment dilemmas associated with the management of sepsis, as well as the high-level pathophysiology, kinetics, and advantages of procalcitonin in comparison to traditional biomarkers of infection. Case studies illuminating the appropriate application of PCT for safely reducing antibiotic exposure will ground viewers in skills they can apply to their practice. Lastly, a brief analysis of clinical and financial outcomes should motivate learners to consider the use of PCT in their patient care.
This session was originally recorded in September 2022 as part of Sepsis Alliance Summit.
Target Audience
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Sepsis Alliance gratefully acknowledges the support provided for this session by Siemens Healthineers.
Michael Broyles, PharmD
Director of Medical Affairs, Biomarkers, ThermoFisher Scientific
Michael Broyles, PharmD, holds degrees and a doctorate from the University of Missouri-Kansas City School of Pharmacy and University of Arkansas for Medical Sciences. Dr. Broyles has more than 30 years of experience as a hospital pharmacy director and laboratory director. He has served as Chairman of pharmacy initiatives for one of the nation’s largest hospital networks for two decades.
Dr. Broyles has engaged in pharmacy initiatives and antimicrobial stewardship consulting for 23 of 40 of the nation’s top integrated networks and consulted for hospitals. He is a second adopter of procalcitonin for management of antibiotic therapy in sepsis, LRTI, and other infections in the United States, having viewed more than 70,000 determinations. He has performed extensive advanced analytics on the performance and value of PCT in most bacterial conditions.
Dr. Broyles participated in the FDA approval process for the use of PCT in sepsis and lower respiratory tract infections. He recently served on the Global Expert Consensus Panel for the use of procalcitonin guidance to optimize its use in bacterial infections. He also serves as Medscape Faculty for Biomarkers and Infectious Diseases and on the Arkansas Department of Health Epidemiology and Antimicrobial Stewardship committees.
No continuing education credits are offered for this session. Content is provided by the sponsor.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.